Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis. Issue 10 (28th June 2019)

• Record Type: Journal Article
• Authors: Amer, Kamil M.; Thomson, Jennifer E.; Congiusta, Dominick; Dobitsch, Andrew; Chaudhry, Ahmed; Li, Matthew; Chaudhry, Aisha; Bozzo, Anthony; Siracuse, Brianna; Aytekin, Mahmut Nedim; Ghert, Michelle; Beebe, Kathleen S.
• Is Part Of: Journal of orthopaedic research. Volume 37:Issue 10(2019)
• Page Start: 2226
• Page End: 2230
• Publication Date: 2019-06-28
• Subjects: epidemiology -- statistics -- cancer/tumors -- SEER -- Chondrosarcoma; Orthopedics -- Periodicals; Musculoskeletal system -- Periodicals; 616.7
• DOI: 10.1002/jor.24387
• Languages: English
• ISSNs: 0736-0266

Abstract

ABSTRACT: Rhabdomyosarcoma is the most common soft‐tissue sarcoma in children and adolescents and accounts for 3% of all pediatric tumors. Subtypes include alveolar, spindle cell, embryonal, mixed‐type, pleomorphic, and rhabdomyosarcoma with ganglionic differentiation. The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was queried for patients diagnosed with any type of rhabdomyosarcoma between 1973 and 2014. Patient demographics, tumor characteristics, and incidence were studied with χ 2 analysis. Survival was modeled with Kaplan–Meier survival curves and Cox proportional hazards models were used to assess the effect of age and gender on survival. Pleomorphic subtype had higher grade and larger sized tumors compared to other subtypes ( p < 0.05). Pleomorphic and alveolar rhabdomyosarcoma had the worst overall survival with a 26.6% and 28.9% 5‐year survival, respectively. Embryonal rhabdomyosarcoma had the highest 5‐year survival rate (73.9%). Tumor size was negatively correlated with survival months, indicating patients with larger tumors had shorter survival times ( p < 0.05). Presence of higher‐grade tumors and metastatic disease at presentation were negatively correlated with survival months ( p < 0.05). No significant differences in the survival were found between gender or race between all of the subtypes ( p > 0.05). This study highlights key differences in the demographic and survival rates of the different types of rhabdomyosarcoma that can be used for more tailored patient counseling. We also demonstrate that large, population‐level databases provide sufficient data that can be used in the analysis of rare tumors. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2226–2230, 2019